{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"To investigate the hematological activity of Plerixafor as measured by Graft Failure. Graft failure is defined as failure of initial engraftment (primary graft failure) or initial engraftment, but subsequent loss of hematopoiesis (secondary graft failure).","groups":[{"description":"Patients who were unable to mobilize a minimum number of cells (CD34+ cell count \\<20 cells/ul)following 5 days of G-CSF mobilization.","id":"OG000","title":"G-CSF Plus Plerixafor"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Subjects Experiencing Graft Failure","type":"SECONDARY","unitOfMeasure":"participants"}